N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=451 Project Breast47: Effect of an Educational Intervention
Breast Neoplasm · Primary Prevention · Risk Factors
Primary: Behavioral BC Risk With an Educational Intervention for Prevention — 8.10; 8.15 units on a scale
N/A N=1,635 Breast Cancer Risk Reduction: A Patient Doctor Intervention
Breast Cancer
Primary: Knowledge of Breast Cancer Risk Factors — 48.9; 56.4 units on a scale
N/A N=10 Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer
Breast Cancer
Primary: Residual Motion During Deep Inspiratory Breath-Hold (DIBH) — 0.27; 0.27 mm
N/A N=232 Predictors of Ovarian Insufficiency in Young Breast Cancer Patients
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
N/A N=1,001 Decision-aid on Breast Cancer Screening
Breast Cancer
Primary: Number of Participants With Adequate Knowledge — 236; 218 participants
Phase 2 N=46 Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer
Breast Neoplasms
Primary: Percent Change in Mammographic Density at 1 Year on Exemestane — -2.4 percent change from baseline
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
N/A N=35 CairnSurgical Breast Cancer Locator (BCL) Post-Market Study
Breast Cancer
Primary: Positive Margin Rate — 2 Participants
N/A N=50,343 Case-Control-Study on the Breast Cancer Risk of Mirena® Compared With Copper IUDs
Breast Cancer
Primary: Breast Cancer Risk — 1076; 1068 participants
Phase 2 N=72 Protocol for Women at Increased Risk of Developing Breast Cancer
Breast Cancer
Primary: Change in Percent of Breast Epithelial Cells Staining Positive for Ki-67 — -1.2; -2.0 percentage of cells staining positive — p=0.71
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=224 Breast Cancer: Feasibility of an Educational Intervention
Women's Health: Neoplasm of Breast
Primary: Feasibility of an Educational Intervention: Adherence to the Intervention — 99; 83 Participants
N/A N=795 Association of Hepatitis C Virus With Breast Cancer
Breast Cancer · Hepatitis C
Primary: Prevalence of HCV Seropositivity in Breast Cancer Patients. — 88; 15; 317; 130 Participants — p=0.0027
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 2 N=48 Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer
Breast Cancer
Primary: Progression-free Survival (PFS) — 6.6; 3.8 Months — p=0.12
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
N/A N=20 Alcohol and Breast Cancer (ABC) Trial
ER+ Breast Cancer · Breast Cancer · Aromatase Inhibitors
Primary: Blood Levels of Total Estradiol Concentration — -0.50; -0.39 Log scale, pg/mL
N/A N=206 Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Breast Cancer
Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR
Phase 2 N=1,075 Green Tea and Reduction of Breast Cancer Risk
Breast Cancer
Primary: Mammographic Density — 22.71; 21.84; 22.09; 21.13 Percent
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Phase 3 N=2,639 European Celecoxib Trial in Primary Breast Cancer
Breast Cancer
Primary: Disease Free Survival (DFS) Benefit of Two Years Adjuvant Therapy With the COX-2 Inhibitor Celecoxib Compared With Placebo in Primary Breast Cancer Patients. — 91; 90…
N/A N=1,071 BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
Breast Cancer
Primary: Number of Eligible Women Who Received Breast Cancer Risk Assessment — 8; 56; 29 Participants
Phase 2 N=58 Vaccination of High Risk Breast Cancer Patients
Breast Cancer · Breast Neoplasms
Primary: Identify a Feasible Schedule of Vaccination Relative to SoC Neoadjuvant Chemotherapy When the Chemovax Are Administered Concurrently. — 3; 2; 4; 2 Participants
Phase 1 N=6 Vaccination of High Risk Breast Cancer Patients
Stage IV Breast Cancer
Primary: Number of Participants With a Dose-limiting Toxicity (Defined as an Adverse Event of Grade 3 or Higher) — 0; 0 participants
N/A N=220 AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival — 9.3 months
Phase 2 N=48 Brostallicin and Cisplatin in Treating Patients With Metastatic Breast Cancer
Triple-negative Breast Cancer
Primary: 3-month Progression-free Survival (3-mo PFS) Rate — 0.511 proportion of participants
N/A N=89 Clinical Utility of a Low-Cost Hand-Held Breast Scanner
Symptomatic Breast Lump
Primary: Number of Quadrants With Detected Breast Lesions — 77; 265 quadrants
N/A N=132 Breast Cancer Genome Guided Therapy Study (BEAUTY)
Invasive Breast Cancer
Primary: DNA From the Germline and Breast Tumor for the Identification of Novel Somatic Changes Within Gene and Gene Pathways. — 3 mutations
Phase 2 N=10 STAR Cape+BKM120 MBC With Brain Met
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR